S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price & News

$10.25
-0.10 (-0.97%)
(As of 04:00 PM ET)
Compare
Today's Range
$10.03
▼
$10.31
50-Day Range
$8.03
▼
$10.70
52-Week Range
$7.09
▼
$11.44
Volume
6.14 million shs
Average Volume
10.74 million shs
Market Capitalization
$11.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.11 Rating Score
Upside/​Downside
6.7% Upside
$10.88 Price Target
Short Interest
Healthy
1.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$799,176 Sold Last Quarter
Proj. Earnings Growth
7.87%
From $2.16 to $2.33 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

827th out of 961 stocks

Pharmaceutical Preparations Industry

398th out of 456 stocks

See Top Rated MarketRank™ Stocks Here

TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEVA Price History

TEVA Stock News Headlines

September 22, 2023 | americanbankingnews.com
UBS Group Boosts Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $11.00
September 20, 2023 | finance.yahoo.com
Unveiling Teva Pharmaceutical Industries (TEVA)'s Value: Is It Really Priced Right? A ...
September 25, 2023 | Altimetry (Ad)
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
September 14, 2023 | seekingalpha.com
Teva: Focus On Innovation And Growth Means The Times They Are A Changing
September 12, 2023 | msn.com
Why Can't You Find Adderall? Inside the Ongoing Shortage of ADHD Medication In US
September 11, 2023 | seekingalpha.com
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
September 2, 2023 | finance.yahoo.com
With 55% ownership of the shares, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is heavily dominated by institutional owners
August 30, 2023 | markets.businessinsider.com
Alkermes Grants Teva License To Market Generic VIVITROL Beginning In Jan., 2027
September 25, 2023 | Altimetry (Ad)
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
August 26, 2023 | seekingalpha.com
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
August 23, 2023 | msn.com
Teva, Glenmark fined $255 million by DOJ to resolve price fixing charges
August 22, 2023 | markets.businessinsider.com
Teva Pharmaceuticals, Glenmark Pharmaceuticals Settle Price-Fixing Charges
August 22, 2023 | proactiveinvestors.com
Teva Pharma lands US$225m fine for price-fixing
August 21, 2023 | msn.com
Generic drug giants settle federal price-fixing charges
August 21, 2023 | edition.cnn.com
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges
August 21, 2023 | finance.yahoo.com
HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major trend -Technavio
August 21, 2023 | uk.finance.yahoo.com
Berlusconi Office Backing $100 Million Pharma Startup Qualifyze
August 15, 2023 | reuters.com
Trial against Teva over kickback claims put on hold amid appeal
August 7, 2023 | finance.yahoo.com
Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market 2018-2028: Key Players Include Teva, Sandoz, Viatris, Sun Pharma, and Others
August 3, 2023 | finance.yahoo.com
Teva Pharmaceutical Industries Limited: Teva Earnings: Robust Gains From Austedo and Ajovy Fuel Sales Growth and Boost Margin
August 3, 2023 | finance.yahoo.com
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
August 3, 2023 | finance.yahoo.com
Teva agrees to pay $126 mln to US hospitals over opioids
August 3, 2023 | finance.yahoo.com
Teva agrees to pay $126 million to US hospitals over opioids
August 3, 2023 | markets.businessinsider.com
Goldman Sachs Keeps Their Hold Rating on Teva Pharmaceutical (TEVA)
August 3, 2023 | bloomberg.com
Murder, Money and the Battle for a Pharmaceutical Empire
August 3, 2023 | finance.yahoo.com
Teva stock pops on Q2 results, CEO sees 'significant' potential for trio of branded drugs
August 2, 2023 | seekingalpha.com
Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Company Calendar

Last Earnings
8/02/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TEVA
CUSIP
N/A
CIK
818686
Web
www.tevapharm.com
Phone
(723) 914-8213
Fax
972-3923-4050
Employees
36,826
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.88
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+5.1%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
4.79
P/E Growth
1.41
Net Income
$-2,353,000,000.00
Net Margins
-14.87%
Pretax Margin
-14.02%
Return on Equity
27.93%
Return on Assets
5.52%

Debt

Debt-to-Equity Ratio
2.43
Current Ratio
1.02
Quick Ratio
0.67

Sales & Book Value

Annual Sales
$14.93 billion
Price / Sales
0.78
Cash Flow
$3.61 per share
Price / Cash Flow
2.87
Book Value
$7.82 per share
Price / Book
1.32

Miscellaneous

Outstanding Shares
1,120,650,000
Free Float
1,113,702,000
Market Cap
$11.60 billion
Optionable
Optionable
Beta
1.17
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Eliyahu Sharon Kalif (Age 50)
    Exec. VP & CFO
    Comp: $2.01M
  • Mr. Eric DrapeMr. Eric Drape (Age 61)
    Exec. VP of Global Operations
    Comp: $1.91M
  • Mr. Mark SabagMr. Mark Sabag (Age 52)
    Exec. VP of International Markets Commercial
    Comp: $1.92M
  • Dr. Sven Dethlefs Ph.D. (Age 54)
    Exec. VP of North America Commercial
    Comp: $1.76M
  • Mr. Richard D. Francis (Age 55)
    Pres, CEO & Director
  • Mr. Amir Weiss (Age 46)
    Sr. VP & Chief Accounting Officer
  • Ran Meir
    Head of Investor Relations
  • Mr. David M. Stark (Age 54)
    Exec. VP & Chief Legal Officer
  • Kathleen Veit
    Sr. VP, Global Compliance & Ethics Officer
  • Ms. Galia Inbar (Age 48)
    Exec. VP, Chief HR Officer & Corp. Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2023?

9 brokerages have issued 1-year price targets for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $14.00. On average, they anticipate the company's stock price to reach $10.88 in the next year. This suggests a possible upside of 5.1% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2023?

Teva Pharmaceutical Industries' stock was trading at $9.12 on January 1st, 2023. Since then, TEVA shares have increased by 13.5% and is now trading at $10.35.
View the best growth stocks for 2023 here.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 16,900,000 shares, a decrease of 18.4% from the August 15th total of 20,710,000 shares. Based on an average daily trading volume, of 10,150,000 shares, the days-to-cover ratio is presently 1.7 days.
View Teva Pharmaceutical Industries' Short Interest.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our TEVA earnings forecast.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.02. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.69 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 27.93% and a negative net margin of 14.87%.

What ETFs hold Teva Pharmaceutical Industries' stock?

ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include iShares MSCI Israel ETF (EIS), VanEck Pharmaceutical ETF (PPH) and VanEck Israel ETF (ISRA).ARK Israel Innovative Technology ETF (IZRL).

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of $2.25-$2.55 for the period, compared to the consensus earnings per share estimate of $2.27. The company issued revenue guidance of $15.00 billion-$15.40 billion, compared to the consensus revenue estimate of $15.02 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.60%), Clal Insurance Enterprises Holdings Ltd (2.82%), Menora Mivtachim Holdings LTD. (2.37%), Lingotto Investment Management LLP (2.16%), Migdal Insurance & Financial Holdings Ltd. (2.11%) and Rubric Capital Management LP (1.67%). Insiders that own company stock include Amir Weiss, David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric A Hughes, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda and Sven Dethlefs.
View institutional ownership trends.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $10.35.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $11.60 billion and generates $14.93 billion in revenue each year. The company earns $-2,353,000,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 36,826 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -